Literature DB >> 29750443

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment.

Alexander Nast1, Lasse Amelunxen2, Matthias Augustin3, Wolf-Henning Boehncke4, Corinna Dressler1, Matthew Gaskins1, Peter Härle5, Bernd Hoffstadt6, Joachim Klaus7, Joachim Koza7, Ulrich Mrowietz8, Hans-Michael Ockenfels9, Sandra Philipp10, Kristian Reich11, Thomas Rosenbach12, Berthold Rzany13, Martin Schlaeger14, Gerhard Schmid-Ott15, Michael Sebastian16, Ralph von Kiedrowski17, Tobias Weberschock18.   

Abstract

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The first section of this short version of the guideline covers systemic treatment options considered relevant by the expert panel and approved in Germany at the time of the consensus conference (acitretin, adalimumab, apremilast, cyclosporine, etanercept, fumaric acid esters, infliximab, methotrexate, secukinumab and ustekinumab). Detailed information is provided on the management and monitoring of the included treatment options.
© 2018 The Authors | Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh：

Year:  2018        PMID： 29750443     DOI： 10.1111/ddg.13516

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


  18 in total

Review 1.  [Treatment of psoriatic arthritis : Are there differential indications?]

Authors:  M Köhm; F Behrens
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

2.  [Health care of chronic inflammatory skin diseases : Do affected individuals seek dermatological care?]

Authors:  M C Schielein; L Tizek; F Seifert; T Biedermann; A Zink
Journal:  Hautarzt       Date:  2019-11       Impact factor: 0.751

3.  Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

Authors:  A B Gottlieb; J F Merola; K Reich; F Behrens; P Nash; C E M Griffiths; W Bao; P Pellet; L Pricop; I B McInnes
Journal:  Br J Dermatol       Date:  2021-07-14       Impact factor: 11.113

4.  De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Panayotis Kaloyannidis; Eshrak Al Shaibani; Miral Mashhour; Mohammed Gamil; Ioannis Apostolidis; Hani Al Hashmi; Khalid Ahmed Al Anazi
Journal:  Case Rep Hematol       Date:  2018-10-16

Review 5.  Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis.

Authors:  Tse-Hung Huang; Chwan-Fwu Lin; Ahmed Alalaiwe; Shih-Chun Yang; Jia-You Fang
Journal:  Int J Mol Sci       Date:  2019-05-24       Impact factor: 6.208

6.  An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis.

Authors:  Yuta Koike; Yumi Fujiki; Maho Higuchi; Reika Fukuchi; Sayaka Kuwatsuka; Hiroyuki Murota
Journal:  JAAD Case Rep       Date:  2019-01-25

Review 7.  IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications.

Authors:  Esther von Stebut; Wolf-Henning Boehncke; Kamran Ghoreschi; Tommaso Gori; Ziya Kaya; Diamant Thaci; Andreas Schäffler
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

8.  Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis.

Authors:  R B Warren; J N W Barker; P Van de Kerkhof; K Reich; U Mrowietz
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-05-10       Impact factor: 6.166

9.  Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.

Authors:  Ploysyne Rattanakaemakorn; Prinpat Pinyowiwat; Wimolsiri Iamsumang; Kumutnart Chanprapaph; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-05-28       Impact factor: 4.162

10.  Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study.

Authors:  Sandra Falkvoll; Sascha Gerdes; Ulrich Mrowietz
Journal:  J Dtsch Dermatol Ges       Date:  2019-01-15       Impact factor: 5.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.